Evidence map›Paper›PMID 26571381›Full record

ArticlePloS one2015

GSE4, a Small Dyskerin- and GSE24.2-Related Peptide, Induces Telomerase Activity, Cell Proliferation and Reduces DNA Damage, Oxidative Stress and Cell Senescence in Dyskerin Mutant Cells.

Laura Iarriccio, Cristina Manguán-García, Laura Pintado-Berninches, José Miguel Mancheño, Antonio Molina, Rosario Perona, Leandro Sastre

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Laura IarriccioInstituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain.
Cristina Manguán-GarcíaInstituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain.
Laura Pintado-BerninchesInstituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain.
José Miguel MancheñoInstituto de Química-Física "Rocasolano" CSIC, Madrid, Spain.
Antonio MolinaAdvanced Medical Projects, Madrid, Spain.
Rosario PeronaInstituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain.
Leandro SastreInstituto de Investigaciones Biomédicas CSIC/UAM, Madrid, Spain.
Universidad Autónoma de Madrid · ESCentro de Investigación Biomédica en Red · ESInstituto de Investigaciones Biomédicas Sols-Morreale · ESInstituto de Química Física Blas Cabrera · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dyskeratosis congenita is an inherited disease caused by mutations in genes coding for telomeric components. It was previously reported that expression of a dyskerin-derived peptide, GSE24.2, increases telomerase activity, regulates gene expression and decreases DNA damage and oxidative stress in dyskeratosis congenita patient cells. The biological activity of short peptides derived from GSE24.2 was tested and one of them, GSE4, that probed to be active, was further characterized in this article. Expression of this eleven amino acids long peptide increased telomerase activity and reduced DNA damage, oxidative stress and cell senescence in dyskerin-mutated cells. GSE4 expression also activated c-myc and TERT promoters and increase of c-myc, TERT and TERC expression. The level of biological activity of GSE4 was similar to that obtained by GSE24.2 expression. Incorporation of a dyskerin nuclear localization signal to GSE24.2 did not change its activity on promoter regulation and DNA damage protection. However, incorporation of a signal that increases the rate of nucleolar localization impaired GSE24.2 activity. Incorporation of the dyskerin nuclear localization signal to GSE4 did not alter its biological activity. Mutation of the Aspartic Acid residue that is conserved in the pseudouridine synthase domain present in GSE4 did not impair its activity, except for the repression of c-myc promoter activity and the decrease of c-myc, TERT and TERC gene expression in dyskerin-mutated cells. These results indicated that GSE4 could be of great therapeutic interest for treatment of dyskeratosis congenita patients.

Indexed as

Cellular SenescenceDNA DamageOxidative StressCell Cycle ProteinsCell NucleusCell ProliferationDyskeratosis CongenitaGene Expression RegulationHEK293 CellsHumansMutationNuclear Localization SignalsNuclear ProteinsPeptide FragmentsPeptidesPromoter Regions, GeneticCell Cycle ProteinsDKC1 protein, humanGSE24.2 peptideGSE4 peptide, humanNuclear Localization SignalsNuclear ProteinsPeptide FragmentsPeptidesTelomerase

Identifiers

PMID26571381
PMCPMC4646510
OpenAlexW2177413804

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.